Newsletters

May 2020 payer newsletter header graphic

ASCO published recommendations on germline and somatic testing of ovarian cancer

May 2020

A new, evidence-based guideline released by the American Society of Clinical Oncology (ASCO) provides recommendations on genetic and tumor testing

Learn More »


graphic of GeneSight TAU chart

Meta-analysis demonstrates significantly improved patient outcomes in major depressive disorder (MDD)

May 2020

GeneSight® cohort outperforms treatment-as-usual (TAU) cohort in every endpoint

Learn More »


graphic with phrase NCCN prostate cancer

NCCN® prostate cancer guidelines say tumor-based molecular testing is appropriate for intermediate and high-risk disease

April 2020

Updated prostate cancer guidelines double the number of risk categories considered appropriate for molecular-based testing.

Learn More »

2020 Newsletters

April 2020 payer newsletter header graphic

ASCO issued evidence-based guidelines for molecular biomarkers in localized prostate cancer

April 2020

The guidelines include recommendations regarding the clinical use and indications of certain prostate cancer biomarkers.

Learn More »


February 2020 payer newsletter header graphic

Advancing precision medicine for pancreatic cancer patients, Myriad obtains expanded BRACAnalysis CDx® indication

Feb 2020

The U.S. Food and Drug Administration (FDA) has approved BRACAnalysis CDx as a companion diagnostic test to Lynparza® (olaparib), a PARP inhibitor.

Learn More »


graphic of data chart

GeneSight test significantly improved outcomes in depressed patients using 6-item Hamilton Scale

Jan 2020

Patients who received the GeneSight test had significantly improved clinical outcomes by week 8 (HAM-D6)

Learn More »


graphic of scientific magazine cover

American College of Rheumatology (ACR) includes Vectra® in their new recommendations on disease activity measures

Jan 2020

Evaluation of its performance and feasibility results in Vectra meeting standards for regular use in clinical settings

Learn More »

2019 Newsletters

graphic with article name

NCCN® expands testing criteria in Clinical Practice Guideline; Elevates importance of pancreatic cancer testing

Dec 2019

Testing criteria for high penetrance genes moves beyond BRCA1/2; Simplifies decision process

Learn More »


graphic of chart

New study demonstrates patients with MDD taking antidepressants with gene-drug interactions benefit from GeneSight

Dec 2019

Published online in Journal of Clinical Psychiatry, Thase et al. assessed patients who entered the GUIDED study on medications with predicted gene-drug interactions

Learn More »


graphic of myPath chart

Dermatopathology experts publishing in SKIN provide guidance for the appropriate use of diagnostic gene expression profiling (GEP) in melanoma

Oct 2019

In their guidance, myPath® Melanoma earned their highest recommendation, “A-strength,” for a clinical scenario which mirrors myPath’s intended use.

Learn More »


graphic of chart

How does Prolaris® improve health outcomes?

Sep 2019

Active surveillance (AS) is appropriate for patients with low-risk prostate cancer.

Learn More »


JCO Precision Oncology, 2019

EndoPredict® accurately estimates absolute chemotherapy benefit at 10 years

Aug 2019

Data published in the ASCO Journal of Precision Oncology further demonstrates EndoPredict’s ability to accurately predict absolute chemotherapy benefit

Learn More »


Science & Innovation Theater Webinars

Kroger Health and Myriad Genetics launch pilot to improve treatment of depression

July 2019

GeneSight® pharmacogenomic test now available to Kroger Prescription Plan members

Learn More »


EndoPredict® Sample Test Report

New data demonstrate EndoPredict® breast cancer prognostic test’s ability to predict chemotherapy benefit and identify patients who can safely forgo extended endocrine therapy

June 2019

Findings promote reduction in overtreatment in ER+/HER2- breast cancer patients

Learn More »


Weighing Clinical and Patient Experience with Hereditary Pan-Cancer Panel Testing

Weighing Clinical and Patient Experience with Hereditary Pan-Cancer Panel Testing

May 2019

Among patients who carried a pathogenic variant (12%), one third of these clinically relevant results were not suspected upon pretest expert assessment

Learn More »


Medicare Issues Favorable Decision for myPath Melanoma

Medicare Issues Favorable Decision for myPath® Melanoma

April 2019

Diagnostic test drives reduction in overtreatment by providing definitive diagnosis for suspicious skin lesion biopsies

Learn More »


NCCN Releases 4th Update to Prostate Cancer Clinical Guidelines

NCCN® elevates its prostate cancer germline testing reference to RECOMMENDED for all risk groups with qualification for Very Low, Low and Intermediate

March 2019

The National Comprehensive Cancer Network (NCCN) recently updated its Prostate Cancer Guidelines

Learn More »


Medicare coverage criteria updates align with NCCN® 2019 Guideline for BRCA1/2 genetic testing

Medicare coverage criteria updates align with NCCN® 2019 Guideline for BRCA1/2 genetic testing

February 2019

Learn More »


Precision Medicine Videos

Intended Use Population for Hereditary Cancer Testing

Chain of Evidence for CU

Variant Classification

Advantages of Panel Testing


Product Info

BRACAnalysis CDx logo
EndoPredict logo
Foresight Carrier Screen logo
GeneSight logo
myChoice CDx logo
myPath Melanoma logo
Myriad myRisk logo
Prequel logo
Prolaris logo
Vectra logo